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Abstract
Abnormal glycosylation is one of the hallmarks of the cancer cell and is associated with tumour
invasion and metastasis. The development of tumour associated carbohydrate antigen (TACA)
vaccines has been problematic due to poor immunogenicity. However when appropriate targets
can be identified, passive immunisation with monoclonal antibodies (mAbs) directed against
TACAs have been shown to have anti-tumour activity. Fas ligand (FasL) is a transmembrane
protein which induces apoptosis in cells expressing its receptor, Fas. When grafted into mice,
FasL-expressing tumour cells break immunological tolerance to self-antigens and induce antibody
mediated tumour immunity. Here, five IgM mAbs were produced from mice vaccinated with
FasL-expressing B16F10 mouse melanoma cells. They recognise various syngeneic and allogeneic
murine tumour cell lines. One mAb, TM10, recognises a range of human tumour cell lines
including melanoma, prostate and ovarian cancer. It does not bind to untransformed cells. The
epitopes recognised by all the mAbs were carbohydrates expressed on proteins. Using
carbohydrate microarrays, the antigenic targets of TM10 were found to be high-mannose core
structures of N-linked glycans. In normal cells high mannose clusters are hidden by extensive
saccharide branching but they become exposed in cancer cells as a result of abnormal
glycosylation pathways. Vaccination with FasL-expressing tumours therefore enables the immune
system to break tolerance to self-antigens, allowing identification of novel TACAs that can form
the basis of future humoral anti-cancer therapy.
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INTRODUCTION
Fas ligand (FasL, CD95L) is a transmembrane protein that induces apoptosis in cells bearing
its receptor, Fas (CD95) (1, 2). Fas is expressed on almost all human tumour cells (3) and so
the FasL/Fas pathway is an attractive target in cancer immunotherapy. However the
systemic administration of FasL is not feasible due to unacceptable hepatotoxicity (3) and so
other approaches have been explored. Perhaps the most interesting finding amongst these is
that when grafted into mice, tumour cells forced to overexpress FasL are rapidly rejected,
and this is followed by the development of a protective, antibody-mediated tumour
immunity (4-6).
Approximately 80% of cell-surface proteins and 5% of lipids are glycosylated (7). Altered
patterns of carbohydrate expression are one of the hallmarks of the cancer cell and changes
include over- and under-expression of naturally occurring glycans, abnormal branching of
glycoproteins and glycolipids, and neoexpression of sugars normally restricted to embryonic
tissue (8, 9). Abnormal glycosylation is associated with tumour cell invasion, metastasis and
angiogenesis (10, 11). Over 50% of cancers known to express the tumour associated
carbohydrate antigens (TACAs) described so far, which include glycolipids (e.g. GM1,
GM2, GD2 and GD3), Lewis antigens such as LeA, LeX and LeY, and Thomsen
Friedenreich (TF) antigen (12).
In this paper we report on the generation of a panel of new monoclonal antibodies (mAb)
from tumour-immune mice following vaccination with FasL-expressing mouse melanoma
cells. One mAb, termed TM10, recognises a broad range of both murine and human tumour
cells. Its carbohydrate epitope, high mannose core structures of N-linked glycans, is a novel
tumour antigen and is described here for the first time.
MATERIALS AND METHODS
Cells and mice
Murine tumour cell lines used include B16F10 melanoma (syngeneic with the C57BL/6
mouse strain), K1735 melanoma (C3H), NS1 myeloma (BALB/c), MC57 fibrosarcoma
(C57BL/6), CT26 colon carcinoma (BALB/c), methylcholanthrene (MCA)-transformed L-
cell fibroblasts (C3H), P815 mastocytoma (DBA/2), and GM95 (ceramide specific
glucosyltransferase deficient cells derived from B16F10 melanoma). FasL expressing
B16F10 cells (B16FasL) were generated as described (6). Human cells used were primary
prostate fibroblasts, dermal fibroblasts, 293T cells, melanoma (Trombelli, MM5), prostate
(PC3, DU145, LN-CAP), breast (ZR75.1, MDA-MB 468), and ovarian cancer cell lines
(PEA-1, PEO-1, SK-OV-3), kind gifts from Professor Jonathan Waxman, Dr Tahereh
Kalamati, Professor Charles Coombes and Professor Hani Gabra, all of Imperial College
London.
Female C57BL/6 mice, aged 5-7 weeks, were purchased from Harlan (Oxon, UK) and
housed at the Central Biomedical Services of Imperial College London. Non-hybridoma
cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated foetal
calf serum (FCS), whilst hybridoma cells were supplemented with 20% batch-tested heat-
inactivated FCS. Media were supplemented with 2mM L-glutamine, 100IU/ml penicillin,
100μg/ml streptomycin and, in the case of murine cells, 50μM 2-mercaptoethanol, 10mM
HEPES, and 1% sodium pyruvate. All cells were incubated at 37°C with 5% CO2.
Generation and purification of mAbs
Murine hybridomas were generated by the fusion of splenocytes and myeloma cells as
previously described (6). Briefly, 1×107 irradiated B16FasL melanoma cells were injected
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subcutaneously into female C57BL/6 mice which were then challenged three times, at
monthly intervals, with 5×105 B16F10 cells. Anti-tumour cell antibody production was
confirmed in mice which rejected these tumour challenges (‘protected mice’) by staining of
B16F10 cells with 1:50 diluted serum, the minimum concentration previously determined by
titration to provide optimal staining. Splenocytes from protected mice with a positive anti-
tumour cell antibody response were fused to NS1 murine myeloma cells using polyethylene
glycol (PEG) 1500 (Roche Diagnostics, Basel, Switzerland). Hybridomas were selected by
culture in HAT (hypoxanthine, aminopterine, thymidine) containing medium, and then
screened by incubating their neat cell culture supernatant with B16F10 followed by anti-
mouse Ig PE (Dako, Glostrup, Denmark). Positive staining hybridomas were single cell
cloned three times and the class and subclass of each mAb determined using Isostrips
(Roche).
Cell culture supernatants from hybridoma colonies were purified over a protein L (Sigma-
Aldrich, Dorset, UK) column, eluted with 0.1M glycine (pH 2.5) and dialysed in sterile
PBS. mAb concentration was measured by spectrophotometer (280nm optical density).
mAbs were titrated and used at 10μg/ml in the mircoarray and 20μg/ml in all other
experiments.
Flow cytometry
Fc receptors on murine cells were blocked with rat anti-mouse CD16/32 (eBioscience, San
Diego, CA) and human cells blocked with human serum (Gibco, Paisley, UK). In some
experiments cells were fixed with 2% formaldehyde and then permeabilised using 0.5%
saponin (Sigma-Aldrich). Secondary antibodies used were anti-mouse IgM FITC (Sigma-
Aldrich) or anti-mouse Ig PE (Dako). A minimum of 2×104 cells were analysed per sample.
Immunohistochemistry
B16F10 cells were grown to confluence on 15mm glass coverslips and then fixed with 1%
formaldehyde. Cells were blocked with 1:200 goat serum and, where indicated,
permeabilised with 0.5% Triton X-100 (Sigma-Aldrich). They were incubated with mAbs
(20μg/ml) and then anti-mouse IgM Alexa Fluor-568 (Molecular Probes, Invitrogen,
Paisley, UK) or anti-mouse IgM FITC. Cells were mounted onto glass slides with
Vectashield/DAPI (Vector Laboratories, Peterborough, UK) and examined by confocal
fluorescent microscopy using a x63 objective (Zeiss LS510, Jena, Germany).
Immunoprecipitation
1×107 native or biotinylated (Biotin EZ-Link – Pierce, Cramlington, UK) B16F10 cells were
lysed in 1ml ice-cold NP40 lysis buffer and, for biotinylated samples, 0.5% Mega-9 (Sigma-
Aldrich). Samples were pre-cleared with Protein L (Sigma-Aldrich), blocked with 10%
bovine serum albumin (BSA), and then incubated with 20μg/ml TM10 followed by 100μL
50% protein L. The immunoprecipitates were run on 12% gels using SDS-PAGE and
developed with silver staining (Amersham Biosciences, Little Chalfont, UK) or analysed by
Western Blot.
Western blot
1×107 B16F10 cells were lysed in ice-cold NP40 lysis buffer, spun supernatants were
separated on 12% gels using SDS-PAGE, and then transferred onto Hybond C Extra
nitrocellulose membrane (Amersham). After being blocking with 5% non-fat dry milk /
PBS, the membrane was incubated with 20μg/ml TM10, and then with anti-mouse Ig HRP
(Sigma-Aldrich). HRP was detected using ECL Western Blotting kit (Amersham).
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Glycosylation inhibitors, competitors, and lectins
B16F10 cells were incubated at 37°C for 24 hours with 200ng/ml tunicamycin (Sigma-
Aldrich) or for 72 hours with 1mM N-butyl-deoxynojirimycin (N-butyl-DNJ) or N-butyl-
deoxygalactonojirimycin (N-butyl-DGJ) (Toronto Research Chemicals, Toronto, Canada).
Alternatively 293T cells or peripheral blood lymphocytes (PBLs) were incubated overnight
with 5μM kifunensine (a gift from Dr Veronica Chang, Institute of Molecular Medicine,
Oxford).
Lectins, with or without conjugation to FITC, were derived from Sambucus Nigra (SNA),
Maakia amurensis (MAA), Concanavalin A (ConA), Phaseolus vulgaris L (PHA-L), and
Galanthus nivalis (GNA) (all Vector Laboratories, Burlingame, CA). D-(+)-mannose, D-(+)-
galactose, D-(+)-glucose, N-acetylglucoasamine (GlcNAc), N-acetylgalactosamine
(GluNAc) and mannose-6-phosphate (all Sigma-Aldrich) were used at 1mg/ml. In some
experiments pre-incubation with lectins or saccharides were used to inhibit binding of
mAbs. In other experiments pre-incubation with the mAbs was used to inhibit the binding of
the lectins or saccharides.
Carbohydrate microarrays
Details of the protocol for the construction of carbohydrate microarrays have been
previously published (13). Briefly, carbohydrate and lipid antigens were printed in triplicate
onto microglass slides using a robotic array spotter. Lipids were used at 0.02-2.0μg/ml and
carbohydrates at 0.5-1.0μg/μ initial concentration, and at a 1:5 dilution. Antibodies to
murine IgM were also printed at given concentrations to serve as standard curves. The
printed slides were blocked with BSA, incubated with the relevant mAb (10μg/ml) and then
anti-mouse IgG or IgM FITC. Analysis was using ScanArray Express Microarray Scanner
(PerkinElmer Life Science, Boston, MA). Fluorescence intensity values for each spot were
calculated with QuantArray software (Parkard Bioscience, PerkinElmer).
RESULTS
Generation of mAbs from B16FasL vaccinated mice
FasL-expressing tumour cells induce development of antibody-mediated tumour immunity
(4-6). mAbs were therefore produced from mice vaccinated with FasL-expressing B16F10
cells (B16FasL) by the fusion of their splenocytes and NS1 myeloma cells. In total 5
monoclonal IgMs (TM3, TM5, TM6, TM10 and TM12) were produced all of which
demonstrated cell surface binding to B16F10 (Figure 1 – top row). The mAbs stained both
B16FasL and B16F10 equally, implying that they are not directed against either FasL or
green fluorescent protein (Figure 1 – bottom row).
mAbs recognise a range of murine and human tumours
The mAbs generated recognised both syngeneic (MC57 fibrosarcoma from a C57BL/6
background) and allogeneic (K1735 melanoma and MCA-transformed L cells, both C3H
background) murine tumour cells (Figure 2). Only one mAb (TM12) recognised P815
mastocytoma, and there was no significant staining of CT26 colon carcinoma by any of the
mAbs. The latter negative results rule out the possibility that the mAbs are just recognising
foetal calf serum in the culture medium or MHC antigens on the tumour cells. There was no
staining of B16F10 or B16FasL with irrelevant murine IgM antibodies or with conjugated
secondary antibodies alone (data not shown).
Since our mAbs recognised a range of murine tumour cells and because human melanoma-
associated antigens can be highly homologous to their murine counterparts (14), binding of
the mAbs to human tumour cells was investigated. Two mAbs – TM10 and TM12 –
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recognised a range of human cancer cell lines (Figure 3). TM10 stained human melanoma
(Trombelli, MM5), prostate (PC3, LN-CAP, DU145), ovarian (PEA-1, PEO-1, SK-OV-3)
and, to a lesser extent, breast cancer lines (MDA-MB 468 and ZR75.1). TM12 stained one
prostate cancer cell line (PC3).
TM10 binds to the intracellular compartment, but not surface, of untransformed cells
Given the broad range of recognition of both murine and human tumour cells, the mAb
TM10 was selected for further investigation. Using indirect immunofluorescence, TM10
was found to have a punctate surface staining pattern of B16F10 cells (Figure 4A). At flow
cytometry there was no cell surface binding of TM10 to a range of untransformed cells
including murine splenocytes and human PBLs (Figure 4B), prostatic fibroblasts and dermal
fibroblasts (data not shown). However when permeabilised with Triton X-100 there was
now strong intracellular staining of both normal and cancer cells (Figures 4A and 4B). This
suggests that all cells have an intracellular reserve of the antibody's epitope but it is only
tumour cells that express it on their surface. There was no staining of any cells by isotype
control antibody using direct immunofluorescence or flow cytometry.
TM10 recognises a carbohydrate, not protein, epitope
A protein epitope for our mAbs was initially sought. However Western blots and
immunoprecipitations from native, surface biotinylated or 35S-methionine labelled B16F10
repeatedly revealed multiple protein bands (Supplemental Figure 1). This raised the
possibility that our mAbs were in fact recognising sugars expressed on more than one
glycoprotein or glycolipid. Experiments using glycosylation inhibitors supported this.
Tunicamycin, a mixture of homologous nucleoside antibiotics, is an inhibitor of N-
glycoprotein synthesis (Supplemental Figure 2). When B16F10 cells were grown in the
presence of tunicamycin, there was a reduction in staining by all the mAbs except TM6
(Figure 5A – top row). The imino sugar N-butyl-deoxynojirimycin (N-butyl-DNJ) is a non-
toxic inhibitor of α-glucosidase and prevents N-glycosylation one step downstream of the
effects of tunicamycin (Supplemental Figure 2). There was reduced binding of all mAbs
(except TM5) when B16F10 cells were pre-treated with N-butyl-DNJ (Figure 5A – bottom
row). As controls, tunicamycin also inhibited the binding of the lectin Con A that binds
preferentially to mannose, and N-butyl-DNJ reduced binding of MAA, a lectin that
preferentially recognises sialic acid which is one of the residues found on N-linked
structures.
The carbohydrates recognised by the mAbs appeared to be restricted to glycoproteins and
are not expressed on glycolipids. Incubation of B16F10 with another imino sugar, N-butyl-
deoxygalactonojirimycin (N-butyl-DGJ) which inhibits ceramide specific
glucosyltransferase and so glycolipid but not glycoprotein formation, had no effect on mAbs
binding (data not shown). Furthermore GM95, a B16F10 derived cell line that has reduced
levels of ceramide specific glucosyltransferase and so impaired glycolipid expression,
showed the same level of surface staining by all the mAbs when compared to B16F10 (data
not shown).
The epitope for TM10 is a high-mannose cluster
With results pointing strongly towards carbohydrate epitopes, we screened our mAbs on a
microarray of carbohydrates and glycolipids. TM10 bound strongly to two of these antigens
(Figures 5B and 5C), both high-mannose clusters, displayed on the array as (Man9)n –
which represents the mannose-core of N-glycoproteins – and [(Man9)4]n which mimics the
mannose clusters displayed by the gp120 glycoprotein of HIV-1 (15, 16). Both mannose
clusters were bound to the carrier keyhole limpet haemocyanin (KLH) but there was only
weak binding of TM10 to KLH alone (Figure 5B). Indeed, when the mean fluorescent
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intensities (MFIs) are compared at 0.1 μg/μl, (Man9)n-KLH and [(Man9)4]n-KLH gave a
14- and 11-fold increase in signal compared to that of KLH alone (Figure 5C). It remains
possible that the TM10 mAb may also have low affinity for some sugar epitopes on KLH.
TM10 did not bind to any other antigens on the array, and there was no significant binding
to the array of any of the other mAbs screened (data not shown).
To confirm the array finding of a high-mannose cluster epitope for TM10, we used the α-
mannosidase inhibitor kifunensine which prevents normal glycoprotein synthesis and leads
to an accumulation of Man9 complexes (Supplementary Figure 2). Treatment of 293T cells
with kifunensine increased the binding of TM10 confirming that the antibody is recognising
mannose clusters (Figure 6A). As expected the expression of sialic acid residues, detected
through binding of MAA, was reduced in the presence of kifunensine. Inhibition
experiments using D-(+)-mannose, D-(+) galactose, D-(+) glucose, D-(+) fucose, N-
acetylglucosamine (GlcNAc), N-acetylgalactosamine (GluNAc) or mannose-6-phosphate to
reduce binding of TM10 to B16F10 were negative (data not shown), suggesting that the
antibody is recognising a more complex structure than just these simple saccharide units.
Several different lectins known to bind to mannose-based carbohydrates were used to stain
B16F10 and competitively inhibit TM10 binding. SNA (binding preferentially to sialic acid
attached to terminal galactose), GNA (preferential binding to α1,3-mannose), and PHA-L
(specific for Galβ1-4 GlcNAc structures) all stained B16F10, indicating that mannose-based
epitopes are present on the cell surface (Figure 6B and data not shown). However there was
no inhibition of lectin binding when cells were pre-incubated with TM10. Furthermore,
when B16F10 cells were pre-incubated with lectins there was no abrogation, but instead an
increase, in TM10 binding. Taken together these findings suggest that the epitopes
recognised by TM10 and the lectins differ, but that the target for TM10 may also be
expressed on the lectins themselves. Lectins are glycoproteins, and SNA for example
contains 7.8% carbohydrates, principally mannose and glucosamine (17).
DISCUSSION
We have previously shown that FasL expressed on B16F10 murine melanoma leads to the
development of antibody-mediated tumour immunity (6). To investigate this humoral
response further, mAbs were produced from tumour immune mice that had been vaccinated
with FasL-expressing melanoma cells (B16FasL). In total five monoclonal IgMs were
generated all of which bound to the cell surface of both B16FasL and B16F10. One mAb,
TM10, binds to both human and murine tumours and its epitope is a novel carbohydrate
tumour antigen, high mannose clusters. The humoral nature of FasL-associated tumour
immunity is important as antibody immunotherapy represents one of the success stories of
immunology and has become established as proven treatment in the fields of oncology and
haematology.
It is known that vaccination with whole tumour cells induces an IgM predominant response
directed against repetitive carbohydrate structures on the cell surface (18). The relative
absence of an IgG response is because the T cell help required for an isotype switch from
IgM to IgG production is missing since carbohydrates are T cell independent antigens. This
raises the question whether the mAbs generated here are just a product of melanoma cell
vaccination as opposed to being specifically induced by the presence of FasL. Although we
did not attempt to make mAbs from mice vaccinated with wild-type B16F10, there are three
reasons why this is not the case. First, in the original description of the B16FasL vaccination
model there was antibody binding to B16F10 from the serum of mice vaccinated with
B16FasL but not from the serum of those vaccinated with wild-type melanoma (6).
Secondly, vaccination with B16F10 was not capable of inducing protection from further
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tumour challenge as other mAbs have previously been shown to do. Finally, only transfer of
serum from B16FasL vaccinated mice conferred tumour protection.
Using FasL expression on tumours as an adjuvant, there is an efficient generation of mAbs
targeting TACAs. TM10 recognises high-mannose clusters which constitute the core of N-
linked glycoproteins. The high-mannose clusters targeted appear not be a major component
of glycolipids since there was no abrogation of TM10 binding in the presence of glycolipid
inhibitors or to cells with impaired glycolipid expression (data not shown). In normal cells,
high-mannose clusters are inaccessible on the surface of cells as they are masked by
extensive N-acetylglucosamine (GlcNAc) branching and sialylation. Consequently TM10
does not bind to the surface of normal, untransformed cells such as murine splenocytes or
human PBLs. In transformed cells abnormal glycosylation pathways (e.g. N-
acetylaminyltransferase mutations) can prevent GlcNAc branching, allowing high-mannose
clusters to become accessible and so facilitating TM10 binding to the tumour cell surface. In
normal cells high-mannose clusters are an intermediary step in the production of N-linked
glycoproteins and as such they exist in abundance in the endoplasmic reticulum. This
intracellular pool is therefore present in all cells, both normal and transformed, and is seen in
the strong TM10 staining of cells that have been permeabilised. This work is the first
description of high-mannose clusters as defined tumour antigens. High mannose clusters
have also been implicated in other pathological processes such as experimental allergic
encephalomyelitis (EAE)1.
Changes in tumour cell glycosylation are associated with invasion and metastasis. Over-
branching of N- and O-linked linked glycans, increased global sialylation and polysialic acid
expression, presence of Lewis antigens and changes in glycolipids have been found to
promote tumour invasiveness, metastasis, angiogenesis and drug resistance in a range of
tumour types (7, 10, 11). Correspondingly such changes have been found to correlate with
poorer prognosis in patients with cancer (8).
New theories have been put forward regarding the role of aberrant glycosylation in cancer.
C-type lectin receptors (CLRs), pattern recognition receptors expressed on many cells
including dendritic cells, recognise not only foreign glycan antigens but also self-antigens.
In doing so they influence cell adhesion, migration and clearance of circulating
glycoproteins (7). Recently it has been shown that antigen-presenting cells use their CLRs to
adhere to carbohydrate structures on tumour cells but not on normal cells (19). It may be that
this process inhibits DC maturation and so represents a mechanism employed by the tumour
cell to evade the immune response. Indeed several pathogens such as HIV-1 and
Lactobacillus have been shown to use sugars to promote the development of regulatory T
cells and to inhibit the generation of an effective T cell response (7, 20).
Abnormal glycosylation on cancer cells makes carbohydrates attractive targets for tumour
immunotherapy. However the development of carbohydrate vaccines has been problematic
as glycans on tumours are insufficiently immunogenic, in part because they can also be
expressed on embryonal tissue and normal tissue (9, 12). The assembly of multi-antigenic
glycan vaccines, incorporation of carriers such as KLH, chemical modification of individual
monosaccharides, and the use of endogenous adjuvants such as α-Gal antibodies have all
been used to improve immunogenicity (9). It has been shown here and in previous studies
(6, 21) that FasL expression on tumour cells is an effective adjuvant in the generation of
carbohydrate recognising antibodies.
1L Steinman – unpublished observations.
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Antibodies directed against TACAs have therapeutic potential. mAbs raised against
synthetically altered polysialic acid and the ganglioside GD3 controlled leukaemia cell
metastases and protected against the development of human melanoma xenografts (22, 23).
KM871, a chimeric IgG1 targeting GD3, induced clinical responses in patients with
melanoma by mediating CDC (24). Meanwhile BR96, directed against the LeY antigen, has
been conjugated to both chemotherapy and toxins although its effects in patients with
metastatic breast and colon carcinomas have been disappointing, partly as a result of dose-
limiting toxicity (25, 26). The presence of naturally occurring anti-GM2 antibodies in
patients with melanoma are associated with an improved survival (27), although more recent
studies have failed to confirm the clinical significance of the antibodies in other cancer types
(28, 29).
Therapeutic mAbs can exert their anti-tumour effects through antibody dependent cellular
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (30). IgMs are the
most efficient isotype for complement activation (30) and, in data not presented here, TM10
was very effective at mediating CDC against B16F10 cells. Others have shown that mAbs
targeting modified tumour-surface carbohydrates kill tumour cells by CDC both in vitro and
in vivo (23, 31). TM10 was found not to be directly cytotoxic nor have any effect on tumour
growth or proliferation (data not shown), supporting the notion that TACAs are involved in
tumour invasion and metastasis, as opposed to roles in cell cycling or survival.
The in vivo anti-tumour effects of TM10 were investigated but were disappointing as it did
not significantly protect mice from the development of new melanomas nor retard the
growth of existing tumours (data not shown). This can be explained as IgM antibodies
predominantly remain in the vasculature, have a shorter biological half-life and do not
mediate ADCC. Indeed most therapeutically successful antibodies are IgGs as this isotype is
the most efficient at mediating Fc domain-based functions such as ADCC. In a previous
panel of mAbs, only the IgG antibody demonstrated anti-tumour activity in vivo, mediated
at least in part by antibody dependent cellular phagocytosis (ADCP) (21). Future work with
TM10 will involve generating an IgG isotype to optimise its in vivo potential.
Vaccination with FasL expressing tumours breaks immunological tolerance to self antigens
and induces antibody-mediated tumour immunity (6). Previous work has shown that these
antibodies are recognising carbohydrates on the tumour cell and, when of the correct
isotype, possess anti-tumour in vivo activity (21). Here we focus on one such mAb, TM10,
which is notable for binding to a range of both murine and human tumour cells. Its epitope,
high mannose clusters, is a novel tumour antigen. In addition to mediating well established
cytotoxic mechanisms such as CDC, TM10 may be interfering with CLR dependent tumour
inhibition of antigen presenting cells. Further work will clarify its activity in vivo activity
and its potential as a therapeutic antibody.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
ADCC Antibody-dependent cellular cytotoxicity
CDC Complement-dependent cytotoxicity
FasL Fas ligand
GNA Galanthus nivalis agglutinin
GlcNAc N-acetylglucosamine
KLH Keyhole limpet haemocyanin
mAb Monoclonal antibody
PHA-L Phaseolus vulgaris Leucoagglutinin
SNA Sambucus nigra agglutinin
TACA Tumour associated carbohydrate antigen
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FIGURE 1.
mAbs were generated from ‘protected’ mice vaccinated with 1×107 irradiated B16FasL cells
and which had rejected at least three subsequent challenges with 5×105 B16F10 cells. Top
row: B16F10 were stained with the mAbs indicated and analysed by flow cytometry. Open
line - staining with mAb indicated. Bottom row: B16F10 (black line) and B16FasL (dashed
line) were stained with the mAbs indicated. In all figures, closed line = isotype control
staining of B16F10.
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FIGURE 2.
mAbs recognise both syngeneic and allogeneic murine tumours. The cell lines indicated
were stained with the relevant mAb and analysed by flow cytometry. Closed line = isotype
control, open line = mAb staining.
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FIGURE 3.
TM10 and TM12 recognise human cancer cells. Human melanoma (Trombelli, MM5),
prostate (PC3, LN-CAP, DU145), ovarian (PEA-1, PEO-1, SK-OV-3) and breast (MDA-
MB468, ZR75.1) cancer cells were stained with the relevant mAb and analysed by flow
cytometry. Closed line = isotype control, open line = mAb staining.
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FIGURE 4.
TM10 binds to the surface of tumour but not to untransformed cells, and there is a large
intracellular reserve of its epitope in all cells. (A) Immunofluorescent microscopy (objective
x63) of B16F10 cells surface stained and intracellular stained (permeabilised with Triton
X-100) with TM10 or isotype control. Bar = 10μm. (B) Surface and intracellular
(permeabilised with saponin) staining of human PBLs with TM10. Closed line - isotype
control, open line = mAb staining.
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FIGURE 5.
The epitope for TM10 is the carbohydrate, high mannose clusters. (A) B16F10 cells were
grown in the presence of (Top row) tunicamycin (inhibitor of N-linked glycosylation) for 18
hours, or (Bottom row) n-butyl-DNJ (inhibitor of α-glucosidase) for 72 hours. They were
then stained with the mAbs indicated and analysed by flow cytometry. ConA - concanavalin
A agglutinin. MAA - maakia amurensis agglutinin. Closed line = isotype control; black line
= staining of untreated cells; dashed line = staining following incubation with relevant
glycosylation inhibitor. (B) Carbohydrate microarray analysis of TM10 (10μg/ml) showing
specific binding to (Man9)n-KLH and [(Man9)4]n-KLH, but not to keyhole limpet
haemocyanin (KLH) alone. (C) Graph of mean fluorescence intensity (MFI) of triplicate
results from the array shown in B. Error bars represent SD.
Newsom-Davis et al. Page 15
Cancer Res. Author manuscript; available in PMC 2009 September 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
FIGURE 6.
TM10 recognises high mannose clusters but the epitope is different to that recognised by
lectins. (A) 293T cells were cultured for 24 hours with or without 5μM kifunensine and then
stained with TM10 or MAA as indicated. Dashed line = plain culture medium; solid line =
kifunsensine. (B) B16F10 cells alone (left-hand graphs, solid line), or pre-incubated with
SNA (top left graph, dashed line) or GNA (bottom left graph, dashed line), were stained
with TM10. Alternatively B16F10 cells alone (right-hand graphs, solid line) or pre-
incubated with TM10 (right-hand graphs, dashed line) were stained with SNA (top graphs)
or GNA (bottom graphs). In all figures closed line = unstained B16F10 cells. MAA =
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maakia amurensis agglutinin, SNA = sambucus nigra agglutinin, GNA = galanthus nivalus
agglutinin.
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